Oct 13, 2021 11:56 AM EDT
New Technology & Licensing Agreements Targeting COVID-19 Virus
At least three new international university-sanctioned studies in Nebraska, St. Louis, New York, and Germany have identified new technological equipment innovations, licensing agreements, and processes assisting in the fight against the COVID-19 and SARS-CoV-2 viruses.
University of Nebraska demonstrates 99.98% success in capturing & destroying COVID-19
San Francisco-based Molekule-a leader in reinventing air purification-announced test results in collaboration with the University of Nebraska Medical Center, Department of Pharmacology & Experimental Neuroscience, which demonstrate that its air purification technology has been successful in removing 99.98% of the COVID-19 virus and SARS-CoV-2 from the air, and destruction rates exceeding 99%.
Many scientific equipment manufacturers and suppliers, among them BMGLabtech, are stepping up their game in response to the COVID-19 challenge, offering customized solutions to detect and destroy viruses.
New waves of the COVID-19 virus have made it clear that cleaner indoor air is a central concern during the pandemic and that air purification technology can provide an extra layer of protection. Molekule's results are from a multiple pass chamber test and swatch level test, respectively, with the multiple pass chamber test utilizing a miniature device in a small chamber with a single injection of virus aerosol, while a swatch level test used Molekule's proprietary "PECO" filter media.
The results build on other peer-reviewed and published validation of Molekule's proprietary PECO technology from the University of Minnesota, in which the company demonstrated the inactivation of coronavirus strains-bovine and porcine-and the H1N1 flu virus.
In a press release, Dr. Siddappa Byrareddy, Professor and Vice-Chair of Research in the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center, and the lead researcher on this study, said: "My team's testing focused on determining Molekule's ability to capture and destroy SARS-CoV-2, specifically the strain isolated from Wisconsin."
Germany's Medical Center Goettingen & Immunic agreement aims to treat viral infections
From New York comes the news that clinical-stage biopharmaceutical company Immunic's attempts to develop a pipeline of selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases have found acceleration with an in-license agreement with the University Medical Center Goettingen, Germany.
Preclinical research has shown that certain DHODH inhibitors-including Immunic's lead asset, IMU-838-strongly synergize with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro, having implications to treat viral infections such as COVID-19 and Influenza.
The company plans to present detailed data at an upcoming scientific conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic said in a press release that the research has revealed a "profound degree of synergy" in vitro when combining nucleoside analogues with DHODH inhibitors, and that in light of recent exacerbations in COVID-19, the company is "very excited" to have licensed this technology to incorporate in its pandemic preparedness efforts.
Y2X Life Sciences licenses solution to diagnose COVID-19
Meanwhile, Y2X Life Sciences-a New York-based leader in products that disrupt the transmission of infectious disease-announced that it has entered into an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology that can detect aerosolized SARS-CoV-2.
Y2X plans to utilize the core technology for applications such as portable units to diagnose COVID-19 from an individual's breath and aerosol detectors that monitor indoor air quality for the presence of SARS-CoV-2 in large gathering places such as airports, conference halls, government facilities, military installations, and vessels and schools.
"We are pleased to partner with Y2X Life Sciences to bring this important technology out of the laboratory and into devices that can help save lives," said team leader Professor John Cirrito, PhD, Washington University in St. Louis's associate professor of neurology.
The technology was put through rigorous diligence as part of the NIH grant process and is an example of the strength research programs and collaboration. The core technology for the biosensor is based on research developed by Cirrito's laboratory currently used for Alzheimer's disease and brain metabolism research.
Join the Conversation